Parabilis Medicines/$PBLS
1D1W1MYTD1Y5YMAX
Capital at risk
About Parabilis Medicines
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
- Ticker
- $PBLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 145
- Headquarters
- Cambridge, United States
- Website
- parabilismed.com
PBLS Metrics
BasicAdvanced
$4.6B
-
-$23.45
-
-
Price and volume
Market cap
$4.6B
52-week high
$42.49
52-week low
$24.51
Average daily volume
780K
Financial strength
Current ratio
17.909
Quick ratio
17.834
Long term debt to equity
0.032
Total debt to equity
0.045
Interest coverage (TTM)
-139.58%
Profitability
EBITDA (TTM)
-169.114
Gross margin (TTM)
-8,750.68%
Net profit margin (TTM)
-115,224.32%
Operating margin (TTM)
-115,907.43%
Management effectiveness
Valuation
Price to revenue (TTM)
2,465.616
Price to book
4.35
Price to tangible book (TTM)
4.35
Price to free cash flow (TTM)
-3.244
Free cash flow yield (TTM)
-30.83%
Free cash flow per share (TTM)
-11.385
Growth
What the Analysts think about PBLS
Analyst ratings (Buy, Hold, Sell) for Parabilis Medicines stock.
Analyst projections of the future price of Parabilis Medicines stock.
Bulls say / Bears say
Zolucatetide has produced a strong early efficacy signal in desmoid tumours: the company reported a 74% response rate in 38 patients, with substantial follow-up in the more mature dose-escalation group. Updated data at ESMO and CTOS could provide a near-term catalyst if the response rate and durability hold up. (StockAnalysis, Parabilis Medicines)
Parabilis has enough capital to pursue its key clinical milestones without an immediate funding need. It ended June with $1.1 billion in cash, cash equivalents and marketable securities, which management expects to fund operations into 2030. (Parabilis Medicines, Parabilis Medicines)
The Regeneron collaboration gives Parabilis external validation for its Helicon platform beyond zolucatetide. It includes $125 million of upfront and equity consideration, potential milestone payments of about $2.2 billion and tiered royalties, while zolucatetide offers possible expansion into several genetically anchored Wnt-driven diseases. (Parabilis Medicines, Parabilis Medicines)
The headline efficacy result is still based on a small, uncontrolled early-stage dataset. Most of the 38 patients came from the more mature dose-escalation arm, while the newer dose-optimisation data are less mature; the planned placebo-controlled Phase 3 trial has not yet begun. (StockAnalysis, Parabilis Medicines)
The shares are being valued on future clinical success rather than current earnings. Parabilis reported a second-quarter loss of $2.32 per share against a $0.16 consensus loss estimate and only $0.15 million of revenue, leaving considerable downside if the programme disappoints. (MarketBeat, Parabilis Medicines)
The mechanism still carries safety and development risk. Management has reported occasional stress fractures at higher doses and says the long-term safety profile of this new approach needs much more data; it is also still discussing the final Phase 3 dose, schedule and endpoints with the FDA. (StockAnalysis, MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
PBLS Financial Performance
Revenues and expenses
PBLS Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBLS News
AllArticlesVideos
Funds containing PBLS
Fund name | Fund size | $PBLS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.